Drugs / UAB30
UAB30
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02876640 | Mar 2018 → Jun 2022 | ductal breast carcinoma in situ, invasive breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01935960 | Aug 2013 → Oct 2016 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01336387 | Oct 2011 → Sep 2012 | — | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00896974 | Aug 2008 → Mar 2010 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03327064 Comparator | Oct 2020 → Aug 2023 | skin cancer | University of Alabama at Birmingham | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UAB30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03327064 ↗ |
| Known as | (9z)-uab-30 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3098771 ↗ |
| Known as | 9-CIS-UAB30 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3098771 ↗ |
| Known as | 9cUAB30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01336387 ↗ |
| Known as | Retinoid 9cuab30 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3098771 ↗ |
| Modality | Other / unclassified | “Retinoid 9cUAB30” NCT00896974 ↗ |
| Route | Oral | “Given orally” NCT00896974 ↗ |